EDMONTON, June 4 /CNW/ - Isotechnika Inc. today announces the successful
results of the Phase 2b PROMISE trial which were presented by Dr. A. Osama
Gaber, an investigator for the PROMISE trial, at the 2008 American Transplant
Congress in Toronto, Canada. The presentation detailed the final data
confirming the efficacy of Isotechnika's next generation calcineurin
inhibitor, voclosporin (ISA247), in de novo kidney transplant patients. An
improved safety profile versus tacrolimus was also reported. Dr. Gaber is the
Director of Transplantation, Vice-Chair for Administration and Faculty
Affairs, Department of Surgery, The Methodist Hospital (Houston) and Cornell
University (New York).
